EMEA-001521-PIP01-13-M06
Table of contents
Key facts
| Invented name |
Reblozyl
|
| Active substance |
Luspatercept
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0155/2022
|
| PIP number |
EMEA-001521-PIP01-13-M06
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
Email: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|